

# Case-finding and improving patient outcomes for chronic obstructive pulmonary disease in primary care: the BLISS research programme including cluster RCT

Peymané Adab,<sup>1\*</sup> Rachel E Jordan,<sup>1\*</sup>  
David Fitzmaurice,<sup>1</sup> Jon G Ayres,<sup>1</sup> KK Cheng,<sup>1</sup>  
Brendan G Cooper,<sup>2</sup> Amanda Daley,<sup>1</sup>  
Andrew Dickens,<sup>1</sup> Alexandra Enocson,<sup>1</sup>  
Sheila Greenfield,<sup>1</sup> Shamil Haroon,<sup>1</sup> Kate Jolly,<sup>1</sup>  
Sue Jowett,<sup>1</sup> Tosin Lambe,<sup>1</sup> James Martin,<sup>1</sup>  
Martin R Miller,<sup>1</sup> Kiran Rai,<sup>1</sup> Richard D Riley,<sup>3</sup>  
Steve Sadhra,<sup>1</sup> Alice Sitch,<sup>1</sup> Stanley Siebert,<sup>4</sup>  
Robert A Stockley<sup>5</sup> and Alice Turner<sup>1,5</sup>

<sup>1</sup>Institute of Applied Health Research, University of Birmingham, Birmingham, UK

<sup>2</sup>Lung Function and Sleep, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

<sup>3</sup>Centre for Prognosis Research, Research Institute for Primary Care and Health Sciences, Keele University, Keele, UK

<sup>4</sup>Business School, University of Birmingham, Birmingham, UK

<sup>5</sup>Respiratory Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

\*Corresponding author [p.adab@bham.ac.uk](mailto:p.adab@bham.ac.uk) and [r.e.jordan@bham.ac.uk](mailto:r.e.jordan@bham.ac.uk)

**Declared competing interests of authors:** Peymané Adab reports grants from the National Institute for Health Research (NIHR) during the conduct of the study. She is chairperson of the NIHR Public Health Research (PHR) Funding Committee and a member of the NIHR PHR Prioritisation Committee. Rachel Jordan reports grants from NIHR during the conduct of the study. David Fitzmaurice reports membership of the NIHR Health Technology Assessment (HTA) Primary Care, Community and Preventative Interventions panel and membership of the NIHR HTA Prioritisation Committee. Kate Jolly reports grants from NIHR during the conduct of the study and is part funded by NIHR Collaboration for Leadership in Applied Health Research and Care West Midlands. She is a subpanel chairperson of the NIHR Programme Grants for Applied Health Research. Sue Jowett reports personal fees from work as an independent advisor at a Pfizer (Pfizer Inc., New York, NY, USA) chronic pain advisory board meeting in November 2018 outside the submitted work and is a member of the NIHR HTA Clinical Evaluation and Trials funding committee and the NIHR HTA programme Funding Board Policy Group. Richard Riley reports grants from NIHR HTA during the conduct of the study and personal fees from the BMJ outside the submitted work. Alice Sitch reports grants from NIHR during the conduct of the study and grants from AstraZeneca (AstraZeneca, Cambridge, UK) Investigator Initiated study outside

the submitted work. Robert Stockley reports personal fees from AstraZeneca, Nycomed (Nycomed, Zurich, Switzerland), Boehringer Ingelheim (Boehringer Ingelheim, Ingelheim am Rhein, Germany), CSL Behring (CSL Behring, King of Prussia, PA, USA), Shire (Shire plc, Lexington, MA, USA), Chiesi (Chiesi Ltd, Manchester, UK), Polyphor (Polyphor Ltd, Allschwil, Switzerland), GlaxoSmithKline (GlaxoSmithKline plc, Brentford, UK), Mereo BioPharma (Mereo BioPharma Group plc, London, UK), Vertex Pharmaceuticals (Vertex Pharmaceuticals, Inc., Boston, MA, USA) and Akari Therapeutics (Akari Therapeutics plc, New York, NY, USA) outside the submitted work. Alice Turner reports grants from NIHR during the conduct of the study; grants, personal fees and non-financial support from AstraZeneca and Chiesi; personal fees and non-financial support from Boehringer Ingelheim; and grants and personal fees from Pfizer outside the submitted work.

Published November 2021

DOI: 10.3310/pgfar09130

## Scientific summary

### BLISS research programme

Programme Grants for Applied Research 2021; Vol. 9: No. 13

DOI: 10.3310/pgfar09130

NIHR Journals Library [www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

# Scientific summary

## Background

At least half of people with chronic obstructive pulmonary disease are undiagnosed, but the best approach for identifying them is not established. Furthermore, screening is not recommended because it is not yet known if it leads to clinical benefits.

There is increasing recognition that chronic obstructive pulmonary disease is heterogeneous, and, although a number of prognostic models have been developed, most prognostic models include people with more severe disease within secondary care. It is not known which combination of phenotypic characteristics best predict prognosis in the larger primary care chronic obstructive pulmonary disease population, particularly in relation to respiratory hospitalisations.

Effective treatment for those with mild chronic obstructive pulmonary disease is limited. Physical activity promotion is a potential intervention, but its acceptability to primary care chronic obstructive pulmonary disease patients is unknown.

A substantial proportion of chronic obstructive pulmonary disease patients are of working age. Although there is some evidence that they have poorer employment history and work productivity, the main factors that are associated with these outcomes have not to our knowledge been previously studied.

The aim of this programme was to address the above uncertainties.

## Objectives

### Work package 1

- Ascertain the clinical effectiveness and cost-effectiveness of targeted case-finding (opportunistic or active) compared with routine care.
- Develop a Markov model to compare the cost-effectiveness of systematic case-finding with current practice.
- Explore the views of patients and primary care staff on chronic obstructive pulmonary disease case-finding.
- Describe the clinical management of screen-detected chronic obstructive pulmonary disease patients in primary care.
- Assess the long-term effectiveness of chronic obstructive pulmonary disease case-finding on respiratory hospitalisations and mortality.
- Compare outcomes among screen-detected chronic obstructive pulmonary disease patients who were adequately managed by their general practitioner with those among patients who were not.

### Work package 2

- Recruit a primary care cohort of 2000 new and existing chronic obstructive pulmonary disease patients.
- Test the validity of existing chronic obstructive pulmonary disease prognostic models in a primary care chronic obstructive pulmonary disease population.
- Develop a prognostic model (BLISS index) to predict respiratory hospitalisations suitable for a primary care population.
- Explore the barriers to and facilitators of physical activity participation among people with chronic obstructive pulmonary disease.

### **Work package 3**

- Examine factors associated with occupational performance [employment, absenteeism and presenteeism (working while unwell)] among chronic obstructive pulmonary disease patients of working age.
- Examine how disease progression is associated with occupational performance.
- Assess the feasibility of offering occupational health assessment with recommendations to people with chronic obstructive pulmonary disease.

## **Methods**

### **Work package 1: TargetCOPD cluster randomised controlled trial**

Fifty-four general practices were randomly assigned to either targeted case-finding or routine care. Eligible patients were people who had smoked, were aged 40–79 years and did not have a previous chronic obstructive pulmonary disease diagnosis. Those in the targeted arm were further randomly assigned to receive a symptom screening questionnaire either at any general practitioner visit (opportunistic) or by post (active). Respondents reporting relevant respiratory symptoms were invited for diagnostic post-bronchodilator spirometry.

Primary outcomes were percentage of the eligible population diagnosed with chronic obstructive pulmonary disease within 1 year (yield) and cost per new chronic obstructive pulmonary disease diagnosis using trial data.

At 4–5 years' follow-up, data on mortality and hospitalisations were obtained from NHS Digital for all eligible patients, and case-found chronic obstructive pulmonary disease patients were invited to complete a health questionnaire to report on their health-related quality of life as well as treatments received for chronic obstructive pulmonary disease. For case-found patients, we also obtained data from electronic health records on whether or not they had been added to the practice's Quality and Outcomes Framework chronic obstructive pulmonary disease register within 12 months and whether or not they had been prescribed a range of chronic obstructive pulmonary disease treatments.

Cox proportional hazards models adjusted for potential confounding factors were used to model the time to clinical outcomes (i.e. death, first respiratory hospital admission) in the intervention and routine arms. Time to event was censored at death (for admission) or study end date if no event occurred.

For case-found patients, we used logistic and Poisson regression to compare mortality, hospitalisation and health-related quality of life among those who were and those who were not added to the chronic obstructive pulmonary disease register, adjusting for baseline values and relevant confounders.

Data from the trial and our cohort study (work package 2) as well as from the published literature were used to develop a Markov decision-analytic model to compare the cost-effectiveness of a 3-yearly case-finding programme aimed at people who have smoked aged > 50 years with current practice, taking a health service perspective.

We interviewed patients who had been invited for screening and primary care staff in targeted case-finding practices to explore their views on screening.

### **Work package 2: Birmingham primary care chronic obstructive pulmonary disease cohort**

Patients aged  $\geq 40$  years with previously diagnosed chronic obstructive pulmonary disease from 71 practices, as well as those reporting chronic respiratory symptoms as part of the TargetCOPD trial, were invited to join the cohort study. Participants underwent detailed baseline assessment, were followed up with 6-monthly questionnaires and underwent a final assessment at  $\approx 3$  years.

Using data from those with chronic obstructive pulmonary disease in the cohort, linked to mortality data obtained from NHS Digital, we sought to validate the ADO (age, dyspnoea, airflow obstruction) prognostic score. This was shown to be the most discriminatory among current indices in predicting mortality in a recent review. Discrimination was calculated using the c-statistic. Calibration was assessed by comparing predicted with actual probability of mortality.

To develop a new index to predict respiratory admissions, we considered 23 candidate variables identified from the literature and by a clinician stakeholder group. Self-reported and clinical data from cohort patients were linked to hospitalisation data obtained through NHS Digital. The primary outcome was the record of at least one respiratory admission within 2 years of cohort entry. The model was developed using backward elimination ( $p < 0.157$  for retention). Fractional polynomials were considered and multiple imputation using chained equations was used for missing data. Discrimination and calibration were assessed. Bootstrapping was used for internal validation and the optimum-adjusted performance statistics were estimated.

A purposive sample of 26 cohort patients with a range of chronic obstructive pulmonary disease severity participated in one of four focus groups to explore perceived barriers to and facilitators of physical activity engagement, using the social cognitive theory framework. Thematic analysis identified key concepts related to the patients' self-efficacy beliefs.

### ***Work package 3: occupational performance and outcomes in chronic obstructive pulmonary disease***

Using baseline data of cohort participants who were of working age, we compared the sociodemographic, clinical and occupational characteristics of people who were in paid employment with those of people who were not. Among those in paid employment, we examined characteristics associated with absenteeism (self-report over previous 12 months) and presenteeism (Stanford Presenteeism Scale).

Longitudinal multivariable regression analyses, adjusting for clinical, sociodemographic, occupational and labour market factors among participants in paid employment, were conducted to examine the effects of disease progression [forced expiratory volume in 1 second decline, respiratory hospitalisations (exacerbations), increase in Medical Research Council dyspnoea score, worsening Chronic Obstructive Pulmonary Disease Assessment Test score] on employment, absenteeism and presenteeism.

Cohort participants who were in paid employment at baseline were invited for a tailored occupational health assessment to explore and identify workplace factors that might contribute to their work performance and to recommend appropriate modifications. Participants' self-management practices were also assessed. Recommendations were sent to the participant and, with their permission, to their general practitioner and employer. We examined acceptability and feasibility of the intervention.

## **Results**

### ***Work package 1***

#### **Effects of case-finding on yield**

A total of 74,818 patients took part. Very few new cases of chronic obstructive pulmonary disease were diagnosed in routine practice. The yield from targeted case-finding was significantly higher (adjusted odds ratio 7.45, 95% confidence interval 4.80 to 11.55) and active case-finding was more clinically effective (adjusted odds ratio 2.34, 95% confidence interval 2.06 to 2.66) and more cost-effective than the opportunistic-only approach (£333 vs. £376 per case detected, respectively).

### **Decision-analytic model of cost-effectiveness of case-finding**

Our model predicted that the incremental cost-effectiveness ratio of a systematic 3-year case-finding programme compared with routine care was £16,596 per additional quality-adjusted life-year gained if assumptions hold, giving this a high probability of being cost-effective using the UK willingness-to-pay threshold of £20,000 per quality-adjusted life-year.

### **Stakeholder views on case-finding**

Both patients and primary care staff generally considered screening to be valuable. Patients highlighted the presence of symptoms and convenience of the screening process as factors promoting screening attendance. Better support from secondary care, an increase in specialist chronic obstructive pulmonary disease nurses and better community respiratory service provision would support primary care staff in undertaking case-finding. Patient barriers to screening attendance included psychological and practical factors, such as time, availability and perceived lack of general practitioner time. Primary care staff had concerns around lack of resource for increasing workload and potential harm from overdiagnosis.

### **Management of case-found patients**

A year after case-finding, approximately one-fifth of case-found patients but > 90% of routinely diagnosed patients had been added to a chronic obstructive pulmonary disease register. Patients who had been added to a chronic obstructive pulmonary disease register were significantly more likely to receive appropriate chronic obstructive pulmonary disease-related care (more than five items of clinical assessment and/or management) than those who had not been added to a register. However, even among those on the register, fewer than one-quarter of eligible patients had ever been referred to pulmonary rehabilitation and a significant proportion of smokers had not received smoking cessation support.

### **Effectiveness of case-finding on clinical outcomes**

Over a mean follow-up of 4.3 years, 4.8% (1557/32,743) of patients in the case-finding arm and 4.5% (1899/41,950) in the routine arm had a respiratory hospitalisation (adjusted hazard ratio 1.04, 95% confidence interval 0.73 to 1.47). The corresponding hazard ratio for mortality was 1.15 (95% confidence interval 0.82 to 1.61), suggesting that, overall, there was no significant difference in risk of hospitalisation and mortality between case-found and routine care arms and there was no noteworthy difference in outcomes between those in the two case-finding intervention arms. Among the case-found patients, when comparing those who were and those who were not on the chronic obstructive pulmonary disease register, there was no statistically significant difference in clinical outcomes or in EuroQol-5 Dimensions scores, although the Chronic Obstructive Pulmonary Disease Assessment Test score was higher in those on the chronic obstructive pulmonary disease register (mean difference 2.317, 95% confidence interval 0.481 to 4.153), indicating greater impact of chronic obstructive pulmonary disease on their health-related quality of life.

## **Work package 2**

### **Birmingham chronic obstructive pulmonary disease cohort**

Data on 2250 patients (97.8%) were available over 3 years. Six-monthly questionnaires were completed by approximately two-thirds of patients. Over the period of follow-up (minimum 1.8 years, maximum 3.8 years), 382 patients (17%) had at least one respiratory hospital admission and 124 patients died.

### **Validation of age, dyspnoea, airflow obstruction prognostic score**

Valid data were available for 1701 chronic obstructive pulmonary disease patients with airflow obstruction (309 case-found patients). Age, dyspnoea, airflow obstruction prognostic scores discriminated 3-year mortality accurately ( $c$ -statistic 0.73, 95% confidence interval 0.67 to 0.79), with similar discriminatory ability for 2- and 1-year mortality ( $c$ -statistic 0.72, 95% confidence interval 0.67 to 0.77 and 0.73 and 95% confidence interval 0.66 to 0.80, respectively). However, there was some overprediction, which was more pronounced at 1- and 2-year mortality time points (calibration

slopes 0.96, 0.80 and 0.79 for 3- 2- and 1-year mortality, respectively) and in those with higher baseline age, dyspnoea, airflow obstruction prognostic scores.

### **Development of the Birmingham Lung Improvement StudieS prognostic index**

Among 1564 previously diagnosed and 330 case-found patients, 253 (13%) had a respiratory admission within 2 years (367 had a respiratory admission over median follow-up of 3 years). Out of 23 candidate variables, six were retained in the final developed model: age, Chronic Obstructive Pulmonary Disease Assessment Test score, respiratory admissions in the previous 12 months, body mass index, diabetes and forced expiratory volume in 1 second percentage predicted. After adjustment for optimism, the primary model performed well in discriminating between those with and without 2-year respiratory admissions (*c*-statistic 0.75, 95% confidence interval 0.72 to 0.79).

### **Barriers to and facilitators of physical activity engagement**

Several barriers to and facilitators of engagement with physical activity, closely related to self-efficacy beliefs and symptom severity, were identified. Barriers were health related, psychological, attitudinal and motivational. Self-regulation (e.g. keeping a routine), self-efficacy (sense of achievement), enjoyment and social aspects of physical activity motivated participation.

### **Work package 3**

#### **Factors associated with occupational outcomes**

Among 608 cohort participants of working age, 248 (40.8%) were in paid employment. Older age (odds ratio 0.28, 95% confidence interval 0.12 to 0.65), lower educational level (odds ratio 0.43, 95% confidence interval 0.19 to 0.97), poorer BODE (body mass index, airflow obstruction, dyspnoea, and exercise) prognostic score (odds ratio 0.10, 95% confidence interval 0.03 to 0.33) and history of high occupational exposure to vapours, gases, dusts or fumes (odds ratio 0.32, 95% confidence interval 0.12 to 0.85) were associated with a lower probability of being employed. Of those in paid employment, higher levels of dyspnoea were associated with both absenteeism and presenteeism (*p*-trend < 0.01). Additionally, occupational vapours, gases, dusts or fumes exposure was associated with presenteeism (*p*-trend < 0.01).

Follow-up data were available for 174 of those in paid employment at baseline. Over a mean follow-up of 25.8 months, 144 (82.8%) participants remained employed. The point estimate suggested an inverse association between increasing respiratory hospital admissions and probability of remaining in work (odds ratio 0.32, 95% confidence interval 0.09 to 1.14; *p* = 0.08), although wide confidence intervals suggest that further research is needed.

Prospective absenteeism data were available for 113 participants (mean follow-up of 19.5 months). Worsening breathlessness (incidence rate ratio 3.06, 95% confidence interval 1.29 to 7.26; *p* = 0.01) and increasing respiratory hospital admissions (incidence rate ratio 2.01, 95% confidence interval 1.09 to 3.69; *p* = 0.03) were associated with increased sickness absence. Follow-up presenteeism data were available for 163 participants (86.2%), where 43 (26.4%) had worsening presenteeism. This was significantly associated with worsening Chronic Obstructive Pulmonary Disease Assessment Test score (odds ratio 5.74, 95% confidence interval 1.18 to 27.83; *p* = 0.03) and there was some evidence of association with worsening dyspnoea.

#### **Occupational health feasibility study**

Only 35 (11.3%) of the eligible patients agreed to take part in the occupational health study. Of these, 80.0% received at least one occupational health recommendation and all received self-management recommendations. However, only 37.3% of recommendations were reported as implementable. The very low uptake rates for the intervention and low implementation of recommendations suggests that, in its current format, the intervention is not feasible.

## Conclusions

Despite screening resulting in higher yield of undiagnosed cases of chronic obstructive pulmonary disease and promising results from our health economic model, we did not find evidence of clinical benefit at 4 years' trial follow-up. The poor clinical management of chronic obstructive pulmonary disease generally, and low addition of case-found patients to the practice chronic obstructive pulmonary disease register, may explain the findings. The benefit of current treatments in case-found patients remains unknown.

For a screening programme to be implemented and have high uptake, it is important to raise patient awareness of chronic obstructive pulmonary disease risk factors and symptoms and provide training and additional resources for primary care. In particular, it is important to ensure that management pathways for diagnosed chronic obstructive pulmonary disease patients are optimised before further cases are identified.

We have developed a new index, using data from people with chronic obstructive pulmonary disease in a UK primary care setting, that has good discrimination performance in predicting respiratory hospitalisations. This needs external validation and examination of its impact on care and outcomes. We confirmed that the age, dyspnoea, airflow obstruction score is discriminatory for predicting mortality in a primary care population.

Among people with chronic obstructive pulmonary disease who are of working age, having greater breathlessness, a greater number of respiratory admissions and greater occupational exposure to vapours, gases, dusts or fumes are associated with poorer work productivity. Although our occupational health intervention was not feasible, modifiable workplace adaptations and self-management actions were identified for almost all participants, suggesting possible benefit from such assessments in a different context.

## Recommendations for further research

- Development and evaluation of interventions to improve management of chronic obstructive pulmonary disease in primary care, including pathways to manage case-found chronic obstructive pulmonary disease.
- Evaluation of existing interventions in case-found chronic obstructive pulmonary disease.
- External validation of the BLISS index in new data.
- Evaluation of impact of using the BLISS index to guide patient management.
- Development and evaluation of interventions to reduce dyspnoea and vapours, gases, dusts or fumes exposure on occupational outcomes in people with chronic obstructive pulmonary disease.

## Trial registration

This trial is registered as ISRCTN14930255.

## Funding

This project was funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research programme and will be published in full in *Programme Grants for Applied Research*; Vol. 9, No. 13. See the NIHR Journals Library website for further project information.



# Programme Grants for Applied Research

ISSN 2050-4322 (Print)

ISSN 2050-4330 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) ([www.publicationethics.org/](http://www.publicationethics.org/)).

Editorial contact: [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

The full PGfAR archive is freely available to view online at [www.journalslibrary.nihr.ac.uk/pgfar](http://www.journalslibrary.nihr.ac.uk/pgfar). Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: [www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

## Criteria for inclusion in the *Programme Grants for Applied Research* journal

Reports are published in *Programme Grants for Applied Research* (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

## Programme Grants for Applied Research programme

The Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was established in 2006 to fund collaborative, multidisciplinary programmes of applied research to solve health and social care challenges. Findings are expected to provide evidence that lead to clear and identifiable patient benefits, in the relatively near future.

PGfAR is researcher led and does not specify topics for research; however, the research must be in an area of priority or need for the NHS and the social care sector of the Department of Health and Social Care, with particular emphasis on health and social care areas that cause significant burden, where other research funders may not be focused, or where insufficient funding is available.

The programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director. For more information about the PGfAR programme please visit the website: <https://www.nihr.ac.uk/explore-nihr/funding-programmes/programme-grants-for-applied-research.htm>

## This report

The research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0109-10061. The contractual start date was in January 2011. The final report began editorial review in February 2019 and was accepted for publication in February 2020. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the PGfAR programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2021. This work was produced by Adab *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library ([www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)), produced by Prepress Projects Ltd, Perth, Scotland ([www.prepress-projects.co.uk](http://www.prepress-projects.co.uk)).

## NIHR Journals Library Editor-in-Chief

---

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

## NIHR Journals Library Editors

---

**Professor John Powell** Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly** Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin** Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson** Consultant Advisor, Wessex Institute, University of Southampton, UK

**Ms Tara Lamont** Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

**Dr Catriona McDaid** Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire** Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Emeritus Professor of Wellbeing Research, University of Winchester, UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma** Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts** Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross** Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)